HRP20210839T1 - Pegilirani rekombinantni spojevi ljudskog hormona rasta - Google Patents
Pegilirani rekombinantni spojevi ljudskog hormona rasta Download PDFInfo
- Publication number
- HRP20210839T1 HRP20210839T1 HRP20210839TT HRP20210839T HRP20210839T1 HR P20210839 T1 HRP20210839 T1 HR P20210839T1 HR P20210839T T HRP20210839T T HR P20210839TT HR P20210839 T HRP20210839 T HR P20210839T HR P20210839 T1 HRP20210839 T1 HR P20210839T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- apcd
- syndrome
- independently
- hgh
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title claims 5
- 108010000521 Human Growth Hormone Proteins 0.000 title claims 5
- 239000000854 Human Growth Hormone Substances 0.000 title claims 5
- 150000001875 compounds Chemical class 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 3
- 208000020221 Short stature Diseases 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 208000005968 HIV-Associated Lipodystrophy Syndrome Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010041092 Small for dates baby Diseases 0.000 claims 2
- 208000026928 Turner syndrome Diseases 0.000 claims 2
- 230000003712 anti-aging effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 208000018773 low birth weight Diseases 0.000 claims 2
- 231100000533 low birth weight Toxicity 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002618 Aarskog syndrome Diseases 0.000 claims 1
- 208000033745 Aarskog-Scott syndrome Diseases 0.000 claims 1
- 208000004611 Abdominal Obesity Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010007710 Cartilage injury Diseases 0.000 claims 1
- 206010065941 Central obesity Diseases 0.000 claims 1
- 206010008723 Chondrodystrophy Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000036119 Frailty Diseases 0.000 claims 1
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 206010053759 Growth retardation Diseases 0.000 claims 1
- 206010019670 Hepatic function abnormal Diseases 0.000 claims 1
- 108700005087 Homeobox Genes Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000007466 Male Infertility Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029748 Noonan syndrome Diseases 0.000 claims 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 1
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 1
- 206010072610 Skeletal dysplasia Diseases 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 208000008919 achondroplasia Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 238000001784 detoxification Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000002283 elective surgery Methods 0.000 claims 1
- 208000012043 faciodigitogenital syndrome Diseases 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 201000010072 hypochondroplasia Diseases 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 210000000629 knee joint Anatomy 0.000 claims 1
- 210000003041 ligament Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 231100000878 neurological injury Toxicity 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000001097 osteosynthetic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
Claims (9)
1. Farmaceutski pripravak, naznačen time, da sadrži prikladna farmaceutska pomoćna sredstva i također sadrži predlijek konjugat ljudskog hormona rasta (hGH) predstavljen formulom (AA):
hGH-NH-La-S0 (AA)
u kojoj
hGH-NH predstavlja hGH ostatak konjugiran s jednim od njegovih primarnih aminoskupina na La;
La predstavlja funkcionalnu skupinu koja se može sama hidrolizirati (samocijepati) putem skupine Ga koja inducira samocijepanje; i
S0 ima formulu (AAA1)
[image]
u kojoj
S00 je CH2; ili C(O);
S0A je alkilenski lanac s jednim do 20 atoma ugljika, koji je opcionalno prekinut ili završava s jednom ili više skupina, cikličkih struktura ili heteroatoma odabranih iz skupine koja se sastoji od opcionalno supstituiranog heterocikla; O; S; C(O); i NH;
BS1, BS2, BS3 se neovisno biraju iz skupine koja se sastoji od N; i CH;
S0C, S1B su (C(O)n2(CH2)n1(OCH2CH2)nOCH3, gdje je svaki n neovisno cijeli broj od 100 do 500, svaki n1 je neovisno 0, 1, 2, 3, 4, 5, 6, 7 ili 8, i n2 je 0 ili 1;
S2, S3 su neovisno vodik; ili (C(O)n2(CH2)n1(OCH2CH2)nOCH3, gdje je svaki n neovisno cijeli broj od 100 do 500, svaki n1 je neovisno 0, 1, 2, 3, 4, 5, 6, 7 ili 8, i n2 je 0 ili 1; uz uvjet da je najmanje jedan od S2, S3 različit od vodika; i
R2, R3 se neovisno biraju iz skupine koja se sastoji od vodika, metila, etila, propila, izopropila, butila, izobutila i tercijarnog butila.
2. Pripravak prema patentnom zahtjevu 1, naznačen time, da se La bira iz skupine koja se sastoji od -C(O)-O, i -C(O)-, koja zajedno s primarnom aminoskupinom od hGH tvori karbamat ili amidnu skupinu.
3. Pripravak prema patentnom zahtjevu 1 ili 2, naznačen time, da konjugat ima formulu (AA1)
hGH-NH-C(O)O-S0 (AA1).
4. Pripravak prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da Ga jest OC(O)-R i R ima formulu I
[image]
gdje se R1, R4, R5 neovisno biraju iz skupine koja se sastoji od vodika, metila, etila, propila, izopropila, butila, izobutila i tercijarnog butila; i
n je 1 ili 2.
5. Pripravak prema patentnom zahtjevu 4, naznačen time, da se R bira iz skupine koja se sastoji od
[image]
[image]
6. Pripravak prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da je najkraća udaljenost između mjesta vezanja za S0 na La i prve razgranate strukture BS1, koja se mjeri kao spojeni atomi, manja od 10.
7. Pripravak prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da farmaceutski pripravak jest pripravak za supkutanu primjenu, intramuskularnu primjenu ili intravenoznu primjenu.
8. Predlijek, naznačen time, da je definiran prema bilo kojem od patentnih zahtjeva 1 do 7.
9. Klinički učinkovita količina farmaceutskog pripravka u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time, da je za uporabu u postupku liječenja bolesti koja se odnosi na GH kod ljudske osobe, pri čemu se bolest koja se odnosi na GH bira iz skupine koja se sastoji od sljedećih: deficijencija hormona rasta; napad deficijencije hormona rasta kod odraslih; Turnerov sindrom; Prader-Willijev sindrom; sindrom kratkih crijeva; kronična bubrežna insuficijencija; djeca premalena za gestacijsku dob (SGA – engl. small for gestational age); iscrpljenost zbog AIDS-a; protiv starenja (engl. anti-aging); reumatoidni artritis; homeobox-genske mutacije za niski rast; somatopauza; Noonanov sindrom; skeletna displazija; Downov sindrom; kratki rast povezan s produljenom uporabom steroida; Aarskogov sindrom; kronična bubrežna bolest; mladenački reumatoidni artritis; cistična fibroza; HIV-infekcija kod djece zbog primanja liječenja HAART; kratki rast kod djece rođene s vrlo niskom porođajnom težinom, osim SGA; hipohondroplazija; ahondroplazija; idiopatski kratki stas; deficijencija hormona rasta kod odraslih; frakture dugih kostiju ili frakture u njima; frakture spužvastog koštanog tkiva ili frakture u njemu; pacijenti nakon operacije tetiva ili ligamenata; distrakcijska osteogeneza; poremećaji kao rezultat zamjene kuka ili diska, popravka meniska, fuzije kralježnice ili fiksiranja proteze; poremećaji kao rezultat fiksiranja osteosintetskog materijala; nesrastanje ili pogrešno srastanje fraktura; poremećaji kao rezultat osteotomije; poremećaji kao rezultat alogene implantacije; degeneracija hrskavice koljenskog zgloba prouzročena ozljedom ili artritisom; osteoporoza kod pacijenata s Turnerovim sindromom; osteoporoza kod muškaraca; odrasli pacijenti na kroničnoj dijalizi (APCD – engl. adult patients in chronic dialysis); kardiovaskularne bolesti kod APCD, povezane s malnutricijom; povratna kaheksija kod APCD; rak kod APCD; kronična opstrukcijska plućna bolest kod APCD; HIV kod APCD; stariji ljudi kao APCD; kronična bolest jetre kod APCD; sindrom zamora kod APCD; Crohnova bolest; oslabljena funkcija jetre; muškarci s HIV infekcijom; centralna pretilost; lipodistrofijski sindrom povezan s HIV-om (HALS – engl. HIV-associated lypodistrophy syndrome); muška neplodnost; pacijenti nakon velike elektivne kirurške operacije, akoholne ili opijatne detoksifikacije ili neurološke ozljede; starenje; krhkost kod starijih ljudi; osteoartritis; traumatska povreda hrskavice; erektilna disfunkcija; fibromialgija; poremećaji pamćenja; depresija; traumatska ozljeda mozga; subarahnoidalna hemoragija; veoma mala porođajna težina; metabolički sindrom; glukokortikoidna miopatija; i kratki rast uslijed glukokortikoidnog liječenja kod djece.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08155408A EP2113256A1 (en) | 2008-04-29 | 2008-04-29 | PEGylated rhGH compounds |
| EP08162865 | 2008-08-22 | ||
| EP08167289 | 2008-10-22 | ||
| EP16156852.2A EP3050576B1 (en) | 2008-04-29 | 2009-04-29 | Pegylated recombinant human growth hormone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210839T1 true HRP20210839T1 (hr) | 2021-08-20 |
Family
ID=40872078
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161040TT HRP20161040T1 (hr) | 2008-04-29 | 2016-08-17 | Pegilirani rekombinantni spojevi ljudskog hormona rasta |
| HRP20210839TT HRP20210839T1 (hr) | 2008-04-29 | 2021-05-25 | Pegilirani rekombinantni spojevi ljudskog hormona rasta |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161040TT HRP20161040T1 (hr) | 2008-04-29 | 2016-08-17 | Pegilirani rekombinantni spojevi ljudskog hormona rasta |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9272048B2 (hr) |
| EP (3) | EP3050576B1 (hr) |
| JP (5) | JP6112766B2 (hr) |
| CN (2) | CN102989001B (hr) |
| BR (1) | BRPI0911780B1 (hr) |
| CA (3) | CA3004716C (hr) |
| CY (2) | CY1117882T1 (hr) |
| DK (2) | DK3050576T3 (hr) |
| ES (2) | ES2875426T3 (hr) |
| HK (2) | HK1152239A1 (hr) |
| HR (2) | HRP20161040T1 (hr) |
| HU (2) | HUE054585T2 (hr) |
| IL (2) | IL208833A (hr) |
| LT (2) | LT3050576T (hr) |
| MX (2) | MX2010011800A (hr) |
| PL (2) | PL2279007T3 (hr) |
| PT (2) | PT2279007T (hr) |
| RU (1) | RU2689336C2 (hr) |
| SI (2) | SI3050576T1 (hr) |
| WO (1) | WO2009133137A2 (hr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005232371B2 (en) * | 2004-03-23 | 2010-10-14 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
| ES2875426T3 (es) * | 2008-04-29 | 2021-11-10 | Ascendis Pharma Endocrinology Div A/S | Compuestos de hormona de crecimiento humana recombinante pegilada |
| DK2306986T3 (en) * | 2008-06-26 | 2018-06-18 | Prolynx Llc | PRODRUGS AND PHARMACEUTICAL Macromolecule Conjugates with Controlled Drug Release Rates |
| CA2739352C (en) | 2008-10-29 | 2021-07-13 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
| KR101581986B1 (ko) | 2008-10-29 | 2016-01-04 | 아블린쓰 엔.브이. | 단일 도메인 항원 결합 분자의 제형 |
| SG178195A1 (en) | 2009-07-31 | 2012-03-29 | Sanofi Aventis Deutschland | Long acting insulin composition |
| MX2012001399A (es) | 2009-07-31 | 2012-03-21 | Sanofi Aventis Deutschland | Profarmacos que comprenden un conjugado de insulina-conector. |
| US8758780B2 (en) | 2009-10-06 | 2014-06-24 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| AU2010311421B2 (en) | 2009-10-29 | 2014-11-20 | Ascendis Pharma A/S | Sterilization of biodegradable hydrogels |
| LT2512450T (lt) * | 2009-12-15 | 2018-04-25 | Ascendis Pharma Endocrinology Division A/S | Sausa augimo hormono kompozicija, laikinai prijungta prie polimero nešiklio |
| WO2011089216A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| WO2011089215A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| US9561285B2 (en) | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
| WO2012007880A2 (en) * | 2010-07-16 | 2012-01-19 | Ablynx Nv | Modified single domain antigen binding molecules and uses thereof |
| EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
| CA2843883C (en) | 2011-08-12 | 2020-04-28 | Ascendis Pharma A/S | Carrier-linked treprostinil prodrugs |
| MX2014001496A (es) | 2011-08-12 | 2014-04-30 | Ascendis Pharma As | Composicion de liberacion sostenida de prostaciclina. |
| JP6363952B2 (ja) * | 2011-12-09 | 2018-07-25 | メタボリック、ファーマシューティカルズ、プロプライエタリー、リミテッドＭｅｔａｂｏｌｉｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｐｔｙ Ｌｔｄ | 成長ホルモン断片の使用 |
| KR101365849B1 (ko) * | 2012-03-28 | 2014-02-24 | 경동제약 주식회사 | 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체 |
| US20150087688A1 (en) | 2012-04-25 | 2015-03-26 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| CA2885169C (en) | 2012-10-11 | 2021-06-22 | Ascendis Pharma A/S | Diagnosis, prevention and treatment of diseases of the joint |
| AU2013353985B2 (en) | 2012-12-07 | 2017-07-13 | Ascendis Pharma A/S | Carrier-linked prostanoid prodrugs |
| CN103976982A (zh) * | 2014-06-03 | 2014-08-13 | 长春理工大学 | 一种包载重组人生长激素缓释药物微囊 |
| DK3653227T5 (da) * | 2014-11-18 | 2023-08-21 | Ascendis Pharma Endocrinology Div A/S | Hidtil ukendte polymere hgh-prodrugs |
| SI3220892T1 (sl) | 2014-11-21 | 2022-01-31 | Ascendis Pharma Endocrinology Division A/S | Oblike odmerjanja dolgotrajno delujočega rastnega hormona |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| SG11201806092TA (en) * | 2016-03-01 | 2018-08-30 | Ascendis Pharma Bone Diseases As | Pth prodrugs |
| US11590207B2 (en) | 2016-09-29 | 2023-02-28 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release PTH compound |
| KR102611820B1 (ko) | 2016-09-29 | 2023-12-07 | 아센디스 파마 본 디지즈 에이/에스 | 낮은 피크 대 트로프 비를 가진 pth 화합물 |
| MA46428A (fr) * | 2016-09-29 | 2019-08-07 | Ascendis Pharma Bone Diseases As | Schéma posologique incrémentiel dans des composés de pth à libération contrôlée |
| AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
| JP2021519336A (ja) * | 2018-03-28 | 2021-08-10 | アセンディス ファーマ オンコロジー ディヴィジョン エー／エス | Ｉｌ−２コンジュゲート |
| TW202015735A (zh) | 2018-05-30 | 2020-05-01 | 法商賽諾菲公司 | 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物 |
| WO2020178273A1 (en) | 2019-03-04 | 2020-09-10 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin |
| JP2023527919A (ja) | 2020-06-03 | 2023-06-30 | アセンディス ファーマ オンコロジー ディヴィジョン エー／エス | Ｉｌ－２配列及びその使用 |
| BR112023003476A2 (pt) | 2020-08-28 | 2023-04-11 | Ascendis Pharma Oncology Div A/S | Proteínas il-2 glicosiladas e usos das mesmas |
| CN112362643A (zh) * | 2020-11-09 | 2021-02-12 | 长春金赛药业有限责任公司 | 一种基于镧系元素化学发光法长效生长激素免疫定量检测试剂盒及其方法 |
| CN114539384A (zh) * | 2020-11-19 | 2022-05-27 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇化长效生长激素及其制备方法和医药应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342832A (en) | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
| US5057417A (en) * | 1987-06-12 | 1991-10-15 | Genentech, Inc. | Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein |
| US5073627A (en) * | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| US5179080A (en) * | 1989-08-31 | 1993-01-12 | Clinical Homecare, Corp. | Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| AU678787B2 (en) | 1992-10-23 | 1997-06-12 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| JP4465109B2 (ja) | 1997-12-17 | 2010-05-19 | エンゾン ファーマシューティカルズ，インコーポレーテッド | アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| US7144978B2 (en) * | 2002-01-15 | 2006-12-05 | Pan Asia Bio Co., Ltd. | Multidrop tree branching functional polyethylene glycol, methods of preparing and using same |
| WO2004019993A1 (en) | 2002-08-30 | 2004-03-11 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
| EP1560599A1 (en) | 2002-11-14 | 2005-08-10 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| JP4279258B2 (ja) | 2002-11-15 | 2009-06-17 | エフ．ホフマン−ラ ロシュ アーゲー | ＰＥＧ ＩＦＮアルファ２ａの位置異性体 |
| US20040142870A1 (en) | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
| US7947261B2 (en) * | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| EP1525890A1 (en) | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Protein-Proteophore complexes |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| AU2005232371B2 (en) * | 2004-03-23 | 2010-10-14 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
| EP1579873A1 (en) * | 2004-03-23 | 2005-09-28 | Complex Biosystems GmbH | Polymeric prodrugs |
| EP1625855A1 (en) * | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Polymeric prodrug with a self-immolative linker |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| EP1836316A4 (en) * | 2004-12-22 | 2009-07-22 | Ambrx Inc | PROCESS FOR EXPRESSION AND CLEANING OF RECOMBINANT HUMAN GROWTH HORMONE |
| US20080207505A1 (en) * | 2005-01-12 | 2008-08-28 | James Kenneth D | Bna Conjugates and Methods of Use |
| EP1850878A2 (en) | 2005-02-10 | 2007-11-07 | Novo Nordisk A/S | C-terminally pegylated growth hormones |
| WO2006094530A1 (en) * | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| EP1861125A2 (en) | 2005-03-23 | 2007-12-05 | Nektar Therapeutics Al, Corporation | Conjugates of an hgh moiety and peg derivatives |
| EP1893239A2 (en) * | 2005-06-15 | 2008-03-05 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of growth hormone |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| US8293869B2 (en) | 2005-12-16 | 2012-10-23 | Nektar Therapeutics | Polymer conjugates of GLP-1 |
| MX2010008024A (es) | 2008-02-01 | 2010-12-21 | Ascendis Pharma As | Profarmaco que comprende un enlazador que se puede separar por si mismo. |
| ES2875426T3 (es) * | 2008-04-29 | 2021-11-10 | Ascendis Pharma Endocrinology Div A/S | Compuestos de hormona de crecimiento humana recombinante pegilada |
| LT2512450T (lt) * | 2009-12-15 | 2018-04-25 | Ascendis Pharma Endocrinology Division A/S | Sausa augimo hormono kompozicija, laikinai prijungta prie polimero nešiklio |
-
2009
- 2009-04-29 ES ES16156852T patent/ES2875426T3/es active Active
- 2009-04-29 PL PL09738181.8T patent/PL2279007T3/pl unknown
- 2009-04-29 BR BRPI0911780-6A patent/BRPI0911780B1/pt active IP Right Grant
- 2009-04-29 EP EP16156852.2A patent/EP3050576B1/en active Active
- 2009-04-29 JP JP2011506705A patent/JP6112766B2/ja active Active
- 2009-04-29 SI SI200932127T patent/SI3050576T1/sl unknown
- 2009-04-29 MX MX2010011800A patent/MX2010011800A/es active IP Right Grant
- 2009-04-29 CN CN201210325582.1A patent/CN102989001B/zh active Active
- 2009-04-29 CN CN200980115469.7A patent/CN102014965B/zh active Active
- 2009-04-29 DK DK16156852.2T patent/DK3050576T3/da active
- 2009-04-29 CA CA3004716A patent/CA3004716C/en active Active
- 2009-04-29 DK DK09738181.8T patent/DK2279007T3/en active
- 2009-04-29 HU HUE16156852A patent/HUE054585T2/hu unknown
- 2009-04-29 SI SI200931492A patent/SI2279007T1/sl unknown
- 2009-04-29 US US12/990,101 patent/US9272048B2/en active Active
- 2009-04-29 MX MX2012008723A patent/MX344559B/es unknown
- 2009-04-29 ES ES09738181.8T patent/ES2587400T3/es active Active
- 2009-04-29 WO PCT/EP2009/055194 patent/WO2009133137A2/en active Application Filing
- 2009-04-29 HU HUE09738181A patent/HUE029926T2/en unknown
- 2009-04-29 EP EP09738181.8A patent/EP2279007B1/en active Active
- 2009-04-29 CA CA2915677A patent/CA2915677C/en active Active
- 2009-04-29 PL PL16156852T patent/PL3050576T3/pl unknown
- 2009-04-29 LT LTEP16156852.2T patent/LT3050576T/lt unknown
- 2009-04-29 LT LTEP09738181.8T patent/LT2279007T/lt unknown
- 2009-04-29 CA CA2721947A patent/CA2721947C/en active Active
- 2009-04-29 PT PT97381818T patent/PT2279007T/pt unknown
- 2009-04-29 PT PT161568522T patent/PT3050576T/pt unknown
- 2009-04-29 EP EP21165572.5A patent/EP3922267A1/en active Pending
-
2010
- 2010-10-20 IL IL208833A patent/IL208833A/en active IP Right Grant
-
2011
- 2011-06-21 HK HK11106349.2A patent/HK1152239A1/zh unknown
-
2013
- 2013-06-25 HK HK13107396.0A patent/HK1179899A1/xx unknown
- 2013-10-02 IL IL228673A patent/IL228673A/en active IP Right Grant
- 2013-12-12 JP JP2013256655A patent/JP6151165B2/ja active Active
-
2014
- 2014-07-21 RU RU2014129893A patent/RU2689336C2/ru active
-
2015
- 2015-09-29 JP JP2015191383A patent/JP6179997B2/ja active Active
-
2016
- 2016-01-19 US US15/000,242 patent/US10098930B2/en active Active
- 2016-08-08 CY CY20161100777T patent/CY1117882T1/el unknown
- 2016-08-17 HR HRP20161040TT patent/HRP20161040T1/hr unknown
-
2017
- 2017-07-13 JP JP2017136679A patent/JP6329673B2/ja active Active
-
2018
- 2018-04-20 JP JP2018081021A patent/JP6704429B2/ja active Active
- 2018-09-28 US US16/146,253 patent/US10960053B2/en active Active
-
2021
- 2021-03-29 US US17/215,991 patent/US20210220442A1/en active Pending
- 2021-05-25 HR HRP20210839TT patent/HRP20210839T1/hr unknown
- 2021-06-18 CY CY20211100545T patent/CY1124332T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210839T1 (hr) | Pegilirani rekombinantni spojevi ljudskog hormona rasta | |
| RU2007145085A (ru) | Опосредованное трансглютаминазой коньюгирование гормона роста | |
| RU2008105545A (ru) | Жидкие препараты пэгилированного гормона роста | |
| RU2006126331A (ru) | Способ конъюгации пептидов, опосредованной трансглутаминазой | |
| SI2512450T1 (en) | A dry growth hormone composition transiently bound to a polymeric carrier | |
| US20070099831A1 (en) | Parathyroid hormone analogues and methods of use | |
| JP2015536314A (ja) | 成長ホルモン送達のための脂肪酸アシル化アミノ酸 | |
| PL195703B1 (pl) | Zastosowanie polipeptydowego analogu peptydu pokrewnego hormonowi przytarczyc | |
| US20070270341A1 (en) | Parathyroid hormone analogues and methods of use | |
| CA2981115C (en) | Anti-dkk-1-anti-rankl bispecific antibody compounds | |
| ES2841123T3 (es) | Formulación del compuesto de la hormona de crecimiento | |
| SIMONS et al. | The microsurgical dissection of a stillborn fetal clubfoot. | |
| CN111971290A (zh) | 用于预防或治疗关节疾病的葡萄糖胺衍生物 | |
| Beguiristain et al. | Femoral anteversion osteotomy for the treatment of hip dislocation in Down syndrome: long-term evolution | |
| Safy | Treatment of Tibial Fractures in Children Using Intra Medullary Nailing | |
| RU2176519C1 (ru) | Способ профилактики потери костной ткани вокруг имплантантов при эндопротезировании | |
| DK200501350A (da) | Use of long-acting growth hormone compositions | |
| SU1666084A1 (ru) | Способ лечени варусной деформации шейки бедренной кости | |
| SU1745224A1 (ru) | Способ лечени спастической эквиноплосковальгусной деформации стопы | |
| Karthikeyan | Outcome and Analysis of Biological Plate Fixation of Comminuted Distal Femur Fracture | |
| SU1598987A1 (ru) | Способ лечени неопорного бедра с дефектом головки и шейки у детей | |
| SU1607789A1 (ru) | Способ изготовлени однополюсного эндопротеза коленного сустава | |
| SU1039485A1 (ru) | Способ оперативного лечени деформирующего артроза коленного сустава | |
| RU1821170C (ru) | Способ реконструкции крыши вертлужной впадины | |
| WO2010128141A1 (en) | Stable pharmaceutical compositions of peptide derivatized using an oxime linker |